Evaluation of respiratory complications in a cohort of preterm infants who did not receive palivizumab monoclonal antibodies

Evaluation of respiratory complications in a cohort of preterm infants who did not receive palivizumab monoclonal antibodies

ABSTRACT Objectives: to analyze the occurrence of respiratory complications over the first year of life in preterm infants who did not receive palivizumab monoclonal antibodies. Methods: analytical retrospective cohort study with preterm infants born between 2012 and 2016 in Uberlândia, state of M...

Full description

Bibliographic Details
Main Authors:	Poliana Castro de Resende Bonati, Maria Cândida de Carvalho Furtado, Débora Falleiros de Mello, Paula Carolina Bejo Wolkers, Gabriel de Oliveira Faria, Daniela Marques de Lima Mota Ferreira
Format:	Article
Language:	English
Published:	Associação Brasileira de Enfermagem 2022-10-01
Series:	Revista Brasileira de Enfermagem
Subjects:	Infant Premature Respiratory Syncytial Viruses Palivizumab Respiratory Tract Diseases Neonatal Nursing.
Online Access:	http://revodonto.bvsalud.org/scielo.php?script=sci_arttext&pid=S0034-71672022001000183&lng=en&tlng=en

Similar Items

Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab
by: Mariana Bueno Manini, et al.

Regional impact of prophylaxis with the monoclonal antibody palivizumab on ospitalizations from respiratory syncytial virus in infants
by: Swiss Medical Weekly
Published: (2001-03-01)

Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29–34 6/7 weeks' gestation in the United States
by: Tianzhou Yu, et al.
Published: (2024-03-01)

Palivizumab e virus respiratorio sinciziale: una panoramica
by: Paolo Manzoni
Published: (2011-07-01)

Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia
by: Jaime E. Ordóñez, et al.
Published: (2024-04-01)

The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence
by: Antonino Capizzi, et al.
Published: (2017-08-01)

Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil
by: Roseane Porfírio de Souza, et al.
Published: (2019-08-01)

Respiratory syncytial virus outbreak in neonatal intensive care unit: Impact of infection control measures plus palivizumab use
by: Silva Camila de A, et al.
Published: (2012-05-01)

Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection
by: Hasindu S. Edirisinghe, et al.
Published: (2023-11-01)

Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era
by: Bernhard Resch, et al.
Published: (2017-04-01)

One‐year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America
by: Leandro Martin Castillo, et al.
Published: (2017-09-01)

Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children
by: Natividad Viguria, et al.
Published: (2021-06-01)

Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada
by: Rodica Gilca, et al.
Published: (2020-12-01)

Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection
by: Bernhard Resch
Published: (2017-09-01)

Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children
by: Saleh al-Alaiyan, et al.
Published: (2015-02-01)

Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation
by: D Wang, et al.
Published: (2008-12-01)

Patient equity and respiratory syncytial virus Immunoprophylaxis
by: H. Cody Meissner
Published: (2019-01-01)

Reappraisal of the Subtropical Guidelines on Palivizumab Prophylaxis in Congenital Heart Disease
by: Shuenn-Nan Chiu, et al.
Published: (2022-01-01)

Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain
by: Ralph Schmidt, et al.
Published: (2017-12-01)

Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016–2017 epidemic season: a systematic review of seven Italian reports
by: Renato Cutrera, et al.
Published: (2019-11-01)

Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?
by: Alessandro Rocca, et al.
Published: (2021-04-01)

RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020
by: Elizabeth R. Packnett, et al.
Published: (2022-11-01)

Resurgence of Respiratory Syncytial Virus in Children: An Out-of-Season Epidemic in Portugal
by: Ana Rita Torres, et al.
Published: (2023-01-01)

Respiratory syncytial virus seasonality in Brazil: implications for the immunisation policy for at-risk populations
by: André Ricardo Ribas Freitas, et al.
Published: (2016-01-01)

Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29–34 wGA) infants without outpatient palivizumab administration
by: Elizabeth R. Packnett, et al.
Published: (2023-08-01)

Survival of recombinant monoclonal and naturally-occurring human milk immunoglobulins A and G specific to respiratory syncytial virus F protein across simulated human infant gastrointestinal digestion
by: Jiraporn Lueangsakulthai, et al.
Published: (2020-10-01)

Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: systematic review and additional economic modelling of subgroup analyses
by: D Wang, et al.
Published: (2011-01-01)

Temporal-spatial analysis of hospitalizations for bronchiolitis in Brazil: prediction of epidemic regions and periods for immunization against the Respiratory Syncytial Virus
by: Edilenia Queiroz Pereira, et al.
Published: (2023-03-01)

Clinical Features of Respiratory Syncytial Virus Infection in Neonates: A Single Center Study
by: Sung Hui Chang, et al.
Published: (2018-11-01)

Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing
by: Kimpen Jan LL
Published: (2002-06-01)

Perinatal respiratory infections and long term consequences
by: Luciana Indinnimeo, et al.
Published: (2015-10-01)

Pathophysiological mechanisms for the respiratory syncytial virus-reactive airway disease link
by: Piedimonte Giovanni
Published: (2002-06-01)

Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006–2010
by: Jesse Papenburg, et al.
Published: (2012-01-01)

Feasibility and ethical issues: experiences and concerns of healthcare workers regarding a new RSV prophylaxis programme in Nunavik, Quebec
by: Armelle Lorcy, et al.
Published: (2020-01-01)

RSV Disease Threat and Innovative Prevention Methods in Health Protection: A Review
by: Paulina Dąbrowska, et al.
Published: (2024-02-01)

Detection of the Onset of the Epidemic Period of Respiratory Syncytial Virus Infection in Japan
by: Hidetomi Yamagami, et al.
Published: (2019-03-01)

Partial Degradation of Recombinant Antibody Functional Activity During Infant Gastrointestinal Digestion: Implications for Oral Antibody Supplementation
by: Baidya Nath P. Sah, et al.
Published: (2020-08-01)

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
by: Abushahin A, et al.
Published: (2018-01-01)

Age-Related Effect of Viral-Induced Wheezing in Severe Prematurity
by: Geovanny F. Perez, et al.
Published: (2016-10-01)

The clinical significance of palivi-zumab in the prevention of severe respiratory infections in newborn infants
by: Bykova Е.М., et al.
Published: (2016-06-01)